Zyentia second round finance

IP2IPO Group PLC
08 June 2004


For Immediate Release                                               8 June 2004

                                IP2IPO Group plc

               Zyentia secures £1,500,000 in second round finance


IP2IPO Group plc (AIM: IPO), the intellectual property company that
commercialises university technology, is pleased to announce that Zyentia
Limited, a spin-out company from the University of Oxford in which IP2IPO holds
an equity stake, has succeeded in raising £1,500,000 in second round finance.

Zyentia was formed in May 2002 to exploit the ground-breaking research of
Professor Chris Dobson FRS in predicting and modifying protein folding.  The
company is targeting its proprietary technology in the development of
therapeutic agents to prevent the misfolding and aggregation of proteins that
cause major diseases such as Alzheimer's and Type II Diabetes.  Zyentia will use
the proceeds to establish its own research laboratories and to take lead
compounds into pre-clinical development.

The financing round, which was well supported by existing shareholders,
capitalises the company at £5.3 million. In line with its business model, IP2IPO
did not subscribe for new shares. Post the completion of the financing, IP2IPO
holds a 13.2% interest in Zyentia.


For more information contact:

 IP2IPO 
 David Norwood, Chief Executive Officer                     020 7071 4348

 Zyentia
 Dr Ian Rubin, Chief Executive Officer                      07958 486769

 Buchanan Communications
 Tim Anderson, Mark Court, Mary-Jane Johnson                020 7466 5000


Notes to editors

IP2IPO

IP2IPO is an intellectual property (IP) company that specialises in
commercialising university technology. The Company has already formed four
long-term partnerships with UK universities and listed on AIM in October 2003.
IP2IPO's first such collaboration was with the University of Oxford. In return
for an investment of £20 million, IP2IPO has acquired 50 per cent of the
University of Oxford's equity in spin-out companies and technology licenses
based on intellectual property created at the Chemistry Department until 2015.

In March 2002, IP2IPO Limited entered into a second long-term partnership with
the University of Southampton. Under the terms of this partnership, IP2IPO is
committed to working with the University of Southampton in the identification
and facilitation of spin-out companies from across the University of Southampton
and to investing £5 million in early-stage University of Southampton spin-out
companies over a four year period in return for equity stakes in those
companies. In addition, IP2IPO Limited received a 20 per cent stake in
Southampton Asset Management Limited, a company that has been formed to hold the
University's equity stakes in its future spin-out companies. The partnership has
a term of at least 25 years.

IP2IPO Limited entered into its third long-term partnership in May 2003 with
King's College London. IP2IPO Limited will work with King's College London to
help identify and progress commercialisation opportunities as well as invest £5
million in King's College London's spin-out companies over a five year period in
return for equity stakes in those companies. In addition, IP2IPO Limited will
receive 20 per cent of King's College London's equity in spin-out companies and
technology licenses. The partnership has a term of 25 years.

In October 2003, IP2IPO announced a fourth partnership with the Centre for Novel
Agricultural Products ('CNAP'), based at the University of York. CNAP is a
flagship research centre that specialises in plant and microbial gene discovery.
Under the terms of the partnership a new company, Amaethon Limited, has been
created which has the right to commercialise CNAP's IP for 25 years. IP2IPO
Limited has committed to invest £1.15m in Amaethon Limited in return for a one
third equity stake in Amaethon Limited (the remaining equity being owned by the
University of York) and will also invest in the spin out companies based on
CNAP's IP which Amaethon Limited creates.
 

                      This information is provided by RNS
            The company news service from the London Stock Exchange